Alkylation

$3.25 Billion Worldwide Ovarian Cancer Drugs Industry 2022 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
Monday, March 28, 2022
General Health, Pharmaceutical, Health, Benchmark, Alkylation, C1-inhibitor, PARP, American Cancer Society, API, III, Genentech, Growth, Coronavirus, Compliance, Ovary, Fibroadenoma, Chemotherapy, Research, Ovarian cancer, Woman, Neoplasm, Incidence, Cancer, Death, Roche, Industry, Paclitaxel, Carboplatin, Create, Efficiency, FDA, Patient, Marketing, Birth control, Pharmaceutical industry, Bevacizumab

The main types of tumors in ovarian cancer drugs are epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, sex cord-stromal tumor.

Key Points: 
  • The main types of tumors in ovarian cancer drugs are epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, sex cord-stromal tumor.
  • Ovarian cancer that began in the epithelial layer protecting the ovary is known as epithelial ovarian cancer.
  • The rising incidence of ovarian cancer is driving the ovarian cancer drugs market.
  • Thus, the increasing incidence of ovarian cancer cases across the globe drives the ovarian cancer drugs market growth.

Lummus' CDAlky Technology Selected for Its Efficiency and Low Emission Fuel Production

Retrieved on: 
Thursday, February 17, 2022
KTA, Industry, Engineering, Multimedia, Technology, Styrene, Yulong River, Alkylation, Oil, Lummus

HOUSTON, Feb. 17, 2022 /PRNewswire/ -- Lummus Technology announced that Shandong Yulong Petrochemical Co., Ltd., a subsidiary of China's Nanshan Group, has selected its CDAlky technology for use in a new 400 KTA alkylation unit.

Key Points: 
  • HOUSTON, Feb. 17, 2022 /PRNewswire/ -- Lummus Technology announced that Shandong Yulong Petrochemical Co., Ltd., a subsidiary of China's Nanshan Group, has selected its CDAlky technology for use in a new 400 KTA alkylation unit.
  • "Our customers count on Lummus to help profitably and safely produce cleaner fuels with lower environmental impact, which is exactly what Lummus' CDAlky technology achieves," said Leon de Bruyn, President and Chief Executive Officer of Lummus Technology.
  • The CDAlky technology will produce alkylate with a high-octane rating and low sulfur concentration without any olefins.
  • Lummus' CDAlky technology is an advanced low-temperature sulfuric acid alkylation process for the production of high quality alkylate.

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio

Retrieved on: 
Monday, February 14, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAN, Multiple myeloma, Integrity, Eli Lilly and Company, NMPA, Motherboard, BCR, Alkylation, Senior, Social conditions in Honduras, Fragment crystallizable region, CD3, Chemistry, CD8A, Company, Kidney failure, National Medical Products Administration, Proteasome inhibitor, MD Anderson Cancer Center, Frost & Sullivan, Anemia, Degenerative disease, Nature, Hope, Autoimmunity, Bevacizumab, LinkedIn, Stock exchange, Marketing, Breakthrough therapy, News, Orphan, Drug development, Patient, Cancer, Food, CMC, Bone, Control, BCMA, HKEX, Environment, CAR, FDA, ODD, Bone marrow, Metabolism, Trial of the century, Pharmaceutical industry, Healthcare, Fine chemical, Food and Drug Administration Safety and Innovation Act, Incyte

In February 2021, IBI326 was granted Breakthrough Therapy Designation by China's National Medical Products Administration (NMPA) for the treatment of R/R MM.

Key Points: 
  • In February 2021, IBI326 was granted Breakthrough Therapy Designation by China's National Medical Products Administration (NMPA) for the treatment of R/R MM.
  • In February 2022, IBI326 was granted "Orphan Drug Designation" by the FDA for the treatment of relapsed/refractory multiple myeloma.
  • IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases.
  • It was also granted Orphan Drug Designation by the U.S. Food and Drug Administration in October 2021.

LUKOIL Selects Lummus Ether and Alkylation Technologies for its Operations in Perm, Russia

Retrieved on: 
Friday, January 14, 2022
Technology, Multimedia, Engineering, Alkylation, Maintenance, Solution, MTBE, Oil, LUKOIL, Lummus

HOUSTON, Jan. 14, 2022 /PRNewswire/ -- Lummus Technology announced it has been awarded a contract from LUKOIL Permnefteorgsintez for a new integrated methyl tertiary butyl ether (MTBE) and alkylation plant at LUKOIL's refinery in Perm, Russia.

Key Points: 
  • HOUSTON, Jan. 14, 2022 /PRNewswire/ -- Lummus Technology announced it has been awarded a contract from LUKOIL Permnefteorgsintez for a new integrated methyl tertiary butyl ether (MTBE) and alkylation plant at LUKOIL's refinery in Perm, Russia.
  • The MTBE unit will use Lummus' CDEtherol technology and the alkylation unit will use Lummus' innovative CDAlky technology.
  • In 2021, LUKOIL selected Lummus' Novolen polypropylene technology for two new petrochemical facilities in Burgas, Bulgaria, and Kstovo, Russia.
  • Lummus Technology is the global leader in developing process technologies that make modern life possible and focus on a more sustainable, low carbon future.

Textile Chemicals Markets: Coating & Sizing, Colorants & Auxiliaries, Finishing Agents, Desizing Agents, Surfactants - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 20, 2021
Textiles, Manufacturing, VOC, Dow Inc., BASF, Union of Textiles, Chemicals and Paper, Modacrylic, Clothing, Adoption, USD, Nature, Alkylation, Polymer, BASF SE, Oil refinery, CAGR, Dehydration, Region, Industry, Textile, Colourant, Growth, Chemical, Synthetic

The "Textile Chemicals Market by Fiber (Natural, Synthetic), Product Type (Coating & Sizing, Colorants & Auxiliaries, Finishing Agents, Desizing Agents, Surfactants), Application (Apparel, Home Textile, Technical Textile) & Region - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Textile Chemicals Market by Fiber (Natural, Synthetic), Product Type (Coating & Sizing, Colorants & Auxiliaries, Finishing Agents, Desizing Agents, Surfactants), Application (Apparel, Home Textile, Technical Textile) & Region - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The driving factor for the Textile Chemicals market is chemicals is growing demand for technical textiles.
  • Also growing adoption of low VOC and biodegradable materials for textile manufacturing is expected to provide lucrative opportunities for the growth of textile chemicals.
  • These Textile Chemicals remove a wide variety of contaminants effectively and economically from numerous hydrocarbon streams in petroleum refineries through non-regenerative and regenerative Textile Chemicals.

Waldenstrom Macroglobulinemia - Market Insight, Epidemiology and Market Forecast - 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021
Health, Pharmaceutical, Peripheral neuropathy, Chlorambucil, II, NHL, HIV disease progression rates, Clinical trial, Algorithm, Diagnosis, Awareness, Mutation, Lymph, Incidence, III, Table, Immunoglobulin M, Acquisition, Non-Hodgkin lymphoma, B-cell lymphoma, Cytopenia, Alkylation, Bortezomib, Patient, Disease, Cyclophosphamide, Tissue, Therapy, Health insurance coverage in the United States, Cladribine, Bone marrow, Plasmapheresis, BTK, Lymphatic system, LPL, Physiology, Comprehension, News, Technology, Pharmaceutical industry, Medical device, Dentistry, Management, Agriculture, Renewable energy, Health insurance, Macroglobulinemia, Epidemiology, EU, Waldenström's macroglobulinemia, Rituximab

This 'Waldenstrom Macroglobulinemia (WM) - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Waldenstrom Macroglobulinemia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Key Points: 
  • This 'Waldenstrom Macroglobulinemia (WM) - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Waldenstrom Macroglobulinemia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • The Waldenstrom Macroglobulinemia market report thoroughly understands Waldenstrom Macroglobulinemia symptoms by including disease definition, symptoms, causes, physiology, and diagnosis.
  • It also provides Waldenstrom Macroglobulinemia treatment algorithms and treatment guidelines for Waldenstrom Macroglobulinemia symptoms in the US, Europe, and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted Waldenstrom Macroglobulinemia (WM) symptoms epidemiology segmented as the Incidence of Waldenstrom Macroglobulinemia, Gender-specific cases of Waldenstrom Macroglobulinemia, Age-specific Cases of Waldenstrom Macroglobulinemia, and Genetic Mutations in Waldenstrom Macroglobulinemia.

Sinopec Successfully Starts Up Seventh Alkylation Unit Utilizing Dupont™ Stratco® Technology

Retrieved on: 
Thursday, December 9, 2021
Engineering, NYSE, Electronics, FREP, Research, Clean technology, SM, Alkylation, Technology, HAZOP, Investor relations, Multinational Gas and Petrochemical Co v Multinational Gas and Petrochemical Services Ltd, Gasoline, MECS, VIB, Life, Transport, Science, FCC, Alkylation unit, Public health, Legislation, Water, Solution, Compliance, Benzene, Sinopec, DuPont, VIA, Oil

The STRATCO alkylation unit at FREP is designed to produce 7,700 bpsd (300 kmta) of alkylate from a mixed butylene FCC feedstock.

Key Points: 
  • The STRATCO alkylation unit at FREP is designed to produce 7,700 bpsd (300 kmta) of alkylate from a mixed butylene FCC feedstock.
  • This startup is the seventh successful STRATCO alkylation technology startup within Sinopec and allows compliance with the China VI standard which limits sulfur content in gasoline to a maximum of 10 ppm by generating low-sulfur, high-octane, low-Rvp alkylate.
  • The STRATCO alkylation technology is a sulfuric acid-catalyzed process that converts low-value, light olefins (propylene, butylene and amylene) into high-value, branched components called alkylate.
  • Licensed and marketed by DuPont as part of its Clean Technologies portfolio, the STRATCO alkylation technology is the world-leading alkylation technology with more than 100 licensed units worldwide and more than 915,000 bpsd (35,800 kmta) of installed capacity.

Sundyne's HMD Kontro Launches Complete Fluid Containment Solution for Hydrofluoric Acid Process Units

Retrieved on: 
Thursday, November 4, 2021
People, Safety, Honeywell, Engineering, HMD, Technology, Ethanol, Goal, EH&S, Gasoline, Environment, Diaphragm, Hydrofluoric acid, Alkylation, Hydrogen, Environmental health, UOP, C22, Life, Corrosion, Literature, Maintenance, API, Solution, NDE, Resistance, HF, FCC, Water, ISO, Lithium, Refractory, Oil, Heating, ventilation, and air conditioning

EASTBOURNE, UK, Nov. 4, 2021 /PRNewswire-PRWeb/ --Specialist in magnetic drive sealless pumps HMD Kontro , has introduced a new pump option specifically designed for use in hydrofluoric acid (HF) alkylation.

Key Points: 
  • EASTBOURNE, UK, Nov. 4, 2021 /PRNewswire-PRWeb/ --Specialist in magnetic drive sealless pumps HMD Kontro , has introduced a new pump option specifically designed for use in hydrofluoric acid (HF) alkylation.
  • HF alkylation combines olefins (primarily a mixture of propylene and butylene) with isobutene in the presence of a hydrofluoric acid catalyst.
  • "Placing an HF alkylation unit downstream of the FCC (fluid catalytic cracking) process allows a refinery to maintain gasoline value and quality while satisfying fuel emissions requirements."
  • Designed for resistance against highly corrosive fluids, the new HMD Kontro application-specific sealless pump ensures conformity with all environmental health and safety standards, protecting people, plant and the environment through complete fluid containment.

Ionic Liquids Market, 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 26, 2021
Food, Beverage, Retail, Biotechnology, Technology, Separation, Industry, Chevron, Solvent, History, Partnership, Ionic liquid, Alkylation, SE, Government, BASF SE, COVID-19, CAGR, Attention, Liquid, BASF, Pet, Lithium, Renewable energy, Fine chemical, Retail

The global ionic liquids market should reach $55.8 million by 2026 from $43.0 million in 2021 at a compound annual growth rate (CAGR) of 5.4% for the forecast period of 2021 to 2026.

Key Points: 
  • The global ionic liquids market should reach $55.8 million by 2026 from $43.0 million in 2021 at a compound annual growth rate (CAGR) of 5.4% for the forecast period of 2021 to 2026.
  • Ionic liquids, a small specialty chemical market, have recently started to receive attention from investors and end-users.
  • The solvents and catalysts segment of the global ionic liquids market is expected to grow from $17.8 million in 2021 to $23.7 million in 2026 at a CAGR of 5.9% for the forecast period of 2021 to 2026.
  • The biotechnology segment of the global ionic liquids market is expected to grow from $6.0 million in 2021 to $8.4 million in 2026 at a CAGR of 7.2% for the forecast period of 2021 to 2026.

Worldwide Multiple Myeloma Drugs Industry to 2026 - Featuring Amgen, Daiichi Sankyo and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 25, 2021
Health, Pharmaceutical, Melphalan, CAGR, Lymphatic system, Multiple myeloma, Transplant, Nanomedicine, Therapy, Lists of diseases, Immune system, Doxorubicin, B cell, Efficiency, Research, Dexamethasone, Disease, Prevalence, R, Alkylation, Anemia, Hypercalcaemia, Bone fracture, Platelet transfusion, Vincristine, Bortezomib, MicroRNA, Thalidomide, Spinal cord compression, Bone marrow, Prednisone, Pharmaceutical industry

The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells.
  • Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents.
  • Looking forward, the publisher expects the global multiple myeloma drugs market to grow at a CAGR of around 10% during the forecast period (2021-2026).